Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
Go back to Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 62.39 +3.04 (5.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.35 | 52 Week High | $0.52 | |||
| Open | $59.05 | 52 Week Low | $0.08 | |||
| Day High | $63.98 | P/E | N/A | |||
| Day Low | $58.34 | EPS | $-3.80 | |||
| Volume | 4,038,805 | |||||
